<SEC-DOCUMENT>0001104659-15-037491.txt : 20150513
<SEC-HEADER>0001104659-15-037491.hdr.sgml : 20150513
<ACCEPTANCE-DATETIME>20150513101429
ACCESSION NUMBER:		0001104659-15-037491
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20150513
FILED AS OF DATE:		20150513
DATE AS OF CHANGE:		20150513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		15856793

	BUSINESS ADDRESS:	
		STREET 1:		91 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		91 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a15-11496_16k.htm
<DESCRIPTION>6-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<div>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Form&nbsp;6-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT TO RULE 13a-16 OR 15d-16</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the Month of May, 2015</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number: 001-37368</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS&nbsp;PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Translation of registrant&#146;s name into English)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">91 Park Drive, Milton Park<br> Abingdon, Oxfordshire OX14 4RY<br> United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;20-F</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;40-F&nbsp;&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No&nbsp;&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No&nbsp;&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108697\15-11496-1\task7409657\11496-1-ba.htm',USER='108697',CD='May 13 12:49 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Other Events</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;12, 2015, Adaptimmune Therapeutics plc (the &#147;Company&#148;) </font><font size="2" style="font-size:10.0pt;">issued a press release announcing that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President,&nbsp;Investor Relations</font><font size="2" style="font-size:10.0pt;">.&#160; The press release is attached as Exhibit&nbsp;99.1 and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;13, 2015, the Company </font><font size="2" style="font-size:10.0pt;">issued a press release announcing that it will present data at the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting</font><font size="2" style="font-size:10.0pt;">.&#160; The press release is attached as Exhibit&nbsp;99.2 and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibits</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Press release dated </font><font size="2" style="font-size:10.0pt;">May&nbsp;12, 2015</font></p>    </td>   </tr>
<tr>
<td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Press release dated </font><font size="2" style="font-size:10.0pt;">May&nbsp;13, 2015</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_122047_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\108697\15-11496-1\task7409657\11496-1-ba.htm',USER='108697',CD='May 13 12:49 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Therapeutics plc</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret   Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate   Secretary</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;13, 2015</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_122136_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\108697\15-11496-1\task7409657\11496-1-ba.htm',USER='108697',CD='May 13 12:49 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a15-11496_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="301" height="66" src="g114961mki001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces Appointment of New Vice President of Investor Relations</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OXFORD, UK and PHILADELPHIA, Pa., May&nbsp;12, 2015 &#151; Adaptimmune (NASDAQ: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President,&nbsp;Investor Relations.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Roberts will lead the company&#146;s investor communications strategies, along with involvement in wider communication programs and activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Roberts brings over 20 years of investor relations, communications, and scientific experience in small, global mid-cap and large cap biotechnology companies to Adaptimmune. He spent ten years (2004-2014) with ViroPharma Incorporated (acquired by Shire in 2014) with responsibility for investor and media relations, patient and physician advocacy, certain branded communications regarding Cinryze&#174; (C1 esterase inhibitor [human]) and other commercial products, and disease awareness, culminating in his service as Vice President, Corporate Communications. &nbsp;His record includes developing award-winning communications programs such as ViroPharma&#146;s investor relations program which won IR Magazine&#146;s 2013 &#145;IR Professional of the Year &#151; Small Cap&#146; and &#145;Grand Prix, Best Overall Investor Relations Program &#151; Small Cap&#146; awards. &nbsp;Previously, Mr.&nbsp;Roberts spent 12 years (1992-2004) with MedImmune Inc. (acquired by AstraZeneca in 2007) in various scientific and investor relations roles of increasing responsibility. Most recently, he served as Vice President,&nbsp;Investor Relations and Corporate Communications for Discovery Labs.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;I am delighted to welcome Will to Adaptimmune,&#148; said James Noble, Chief Executive Officer of Adaptimmune. &#147;Adaptimmune has only recently evolved into a public company, and his wealth of communications experience in U.S. biotechnology companies that have been highly lauded for their investor communications programs and transparency will be essential in order for us to continue our evolution.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Roberts said, &#147;Adaptimmune has come a long way in a short amount of time, thanks to its remarkable people and technology. I am thrilled to join this excellent team, and look forward to contributing as we move forward.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform.&#160; Established in 2008, the company aims to utilize the body&#146;s own machinery &#151; the T cell &#151; to target and destroy cancer cells by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune&#146;s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June&nbsp;2014, Adaptimmune</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901916\15-11496-1\task7410083\11496-1-mk.htm',USER='c901916',CD='May 13 17:51 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 100 employees.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains &#147;forward-looking statements,&#148; as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as &#147;believe,&#148; &#147;may&#148;, &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and other words of similar meaning. </font><font size="2" style="font-size:10.0pt;">&#160;These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Prospectus filed with the Securities and Exchange Commission on May&nbsp;7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.&#160; We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune Contacts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(215) 966-6264</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of PR</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mob: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C901916\15-11496-1\task7410083\11496-1-mk.htm',USER='c901916',CD='May 13 17:51 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a15-11496_1ex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="301" height="66" src="g114961mmi001.jpg"></font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OXFORD, UK and PHILADELPHIA, Pa., May&nbsp;13, 2015 &#151; Adaptimmune Therapeutics plc&#160; (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data at the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting.&#160; The data in this presentation pertain to the phenotypic and functional evaluation of&#160; engineered T cells targeting NY-ESO-1 in the blood of patients following infusion in Phase 1/2 clinical studies in synovial sarcoma and multiple myeloma patients.&#160; This presentation follows the data on persistence and clinical responses in both studies as presented at the recent AACR conference in Philadelphia, PA in April.&#160; The ASGCT meeting will take place at the Hyatt Regency in New Orleans, Louisiana, May&nbsp;13 &#151; 16, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Friday, May&nbsp;15, 2015</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Oral Presentation</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Session title: Cancer &#151; Immunotherapy, Cancer Vaccines I</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Abstract number: 551</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Presenter: Luca Melchiori, Ph.D., Senior Scientist at Adaptimmune</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: &#147;Enhanced-affinity NY-ESO-1-specific T cells exhibit extended functionality without exhaustion in a pattern of effector and memory programming in multiple cancer indications&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Presentation Time: 3:30 pm to 3:45 pm</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Location: Empire D</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform.&#160; Established in 2008, the company aims to utilize the body&#146;s own machinery &#151; the T cell &#151; to target and destroy cancer cells by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune&#146;s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June&nbsp;2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The company currently has over 100 employees.&#160; For more information: http://www.adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains &#147;forward-looking statements,&#148; as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as &#147;believe,&#148; &#147;may&#148;, &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and other words of similar meaning. </font><font size="2" style="font-size:10.0pt;">&#160;These forward-looking statements involve certain risks and uncertainties. Such risks</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\107996\15-11496-1\task7410139\11496-1-mm.htm',USER='107996',CD='May 13 18:38 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our final Prospectus filed with the Securities and Exchange Commission on May&nbsp;7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.&#160; We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune Contacts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T:&#160; (215) 966-6264</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of PR</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mob: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\107996\15-11496-1\task7410139\11496-1-mm.htm',USER='107996',CD='May 13 18:38 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g114961mki001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g114961mki001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!"`2T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBJ.H:Q
MI^F211WMTD#S'";N]-)O1`7<C.,\TM>;>)=-U_3K[^W8-1>[B'*S1G_5KZ8'
M&VNE\)^*H]>@,$^V.]B&74<!Q_>'^%;2HM0YXNZ(4M;,Z2D)P,FFR2)#&TDC
M!$0$LQ.`!7E7B+Q9J7BG4/[)T191;,VU5CX:;W)[+7-*2B=N&PL\1*RT2W?8
M]7SFEKD-%8^#-)6/Q%KD9WX\N%N?+]@>I'Z5UD<B2QK)&P9'`*L.A%-.YE5I
M<CT=UT?1CZ***9D%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`UF"*68X51DGT%<1J6G:+XVN)+C3]49
M;Y5VB.3[I`_V3SCW%=K/"MQ;R0.2%D4J<'!P1BO/M1\!ZEI^I17.@,75/F4O
M(%:-AVSW%=-#E3?O69$[]BGH&LWGAG56T?55)M&;RY(WY"9_B'M4>O64GA'Q
M/#>V/$#GS8O3'\2_3^AKH?%_AF_UR&RNK>W3[8J;9UW@=O7OSFG:YX=U35?"
M>G6[1*^HVQ`<%P!C&#ST["NE5874N^C,^5[%#XB^(P=$M+.T?`OT$KD'GR_3
M\3_*J^FB#P+X0&JR1*^JZ@`(E;^$'D#Z`<FJ<O@CQ'?7UC]IM8Q!;JD3'SE.
M%#9)Q^-:_CGPSKFOZM;_`&*"-K2&(*K&0#!)YX_`5Y%1-3DU\CZ.C*C[*G1<
MDD]9:_A_78YS1/#5]XLEEUC5KQH;0$E[B0\MCJ%SP`*]!\+ZEHC0'1](O'N1
M9IU?)R,]CW_"LCQ;X?UFZTFQT;1($^Q0H/-'F!-Q'0<]>YJ]X2\%P^'@EW)-
M(]Z\>V7#?(,\X`_K2BFG9(C$UJ=:BY2E_ABNGJ=36#XMUJ72-+46A_TRY<1P
M#&3GN<=__KUO5QUL?^$C\=27/WK/21LCYX:3U_SZ"NNE%-\SV1XDGT1I>$-:
MGU;39([X_P"FVLACF!7!]CC]/PK?KC+[_BF_',-\/EL]4'ER^@?U_/'ZUO\`
MB'6H]!TF2\90[_=C0G[S'I53A>2<>HD[+7H:E<UX[O+FRT*.6TN)()#<HI:-
ML''/%4;/PYK6LPK?:MK5Q`\HW)#!P$!Z?_JK)\6#6--T^+3-1G^W6\DRO!=$
M88$9RK?G6E*E'VB5[BE)VV/1HB3$A)R2HI]8^K6&J7]K;1Z=J7V$`?O6"Y)&
M.,5D3^%-:MHFGL?$=T]PHSMD^ZY]*QC"+WE8IM]CKZ*XB7Q)>7_@.YO%D:WO
MK=Q%(\?'((Y'X4[3;;7/%-A#//J,MC8A`JK'_K)L=6)]S5>Q:5Y.W07-V.UK
M%\3ZW-H=A#<01)(TDRQD/G&#6!?1ZWX,:.]2_DU'3=X66.7[R`_YZU#XY@GN
MK6VU2+4I&L[AXQ';8^521][KUJZ=)<ZN[IB<M&=\#D`^M9NE_P!L_;+[^TC#
M]G\S_1?+Z[??].M4-+T#5[.^BN+GQ'<7<2_>A=,!N/K618ZIJ#IXI+WDS?9B
M?(RW^K^]T]*A4[I\K3V_,=^YW-%<+H=IK?B?289;O59[:T0%1Y9_>3$=6)],
M_P`J@N+W7O!^HK8"X;4HKM,6QEZA\X'_`.KO3]AJXIZAS];'H-%<A)X1UBXA
M^TS>(KG[?]X;>(U/I3_#^MWU[H.IPWK8O=/5T:0<$G:<'ZC%2Z2M>+N/F[HZ
MRBN"\/PZ[XHTB+[3JD]M:Q$J73F2<YSDGT'`_"H[RZUOP3?)%]J;4;2Z4B$2
MGD/V_F/K5>PU<4]1<^E['H-%<@?">L7L/VF[\07"7K#<%CXC0^F*;H.N:A-I
MFKV%_(3?:=&^)1U(P<'ZY%3[)-7B[CYNYV-%8/@N[N+WPS;SW4SS2L6R[G)/
M-0>.KVZL-#26TN)()#.JEHS@X]*E4W[3D#FTN=+17$>)=6U6SUS2(K"9V::$
M?N=V%D8G`W5:E\(ZM<1FXF\1W/VWJ-O$:^P%7[)))RE:X<W9'6T5R7AGQ'<?
M8]0M]9<&?3,[W[LHS^N1^-5].M=7\8(=0N]1FL;!V/D06YP2!W)I>Q:;YG9(
M.;L=K17%33:GX,U"V^T7TE_I5P_EGS?OQ'ZUV@((!!R#T-3.'+9[IC3N1W,K
M0VLLJ)O:-"P7^\0.E>73ZGK?C35XH[426Z+\N(G8+&.Y8CK7JM<5XLUV_P!`
ME&GZ9816T<XRDZ+RQ[X`[UMAGJTEJ1/8SO'.IFW-EHUE<RE[9!YC)(02V,`$
M^O?\:F\57%QI/A'2M-:YD%TV&D<.0V`.<GKU/Z5#X>\-FT8^(/$3&&.(^8J2
MGYG;U;_"L]FN?'/BP85D@!Q_USB!_F?ZUTQ4;I=(ZM^9#O\`>95_+J&BWVEW
M3W=UMEBCN"&F;!.[D=>G`K=^)#7<&H6.JV=W.+>YB`!CD8)D<CH<<@_I6_X_
M\.?VEH4<UG%F:P&511]Z/'(_3-<_X7U*R\2Z"WA75I-DJC_1)3UXZ`>X].XK
MQJCYIR\]3Z?#S7L:=5*_)I+T[ESQ/'=^)O#EEKNC3SEXH]MQ##(P/OP.I!_2
MK?@+Q9?ZQ)_9=W`'-K%EKC)#$#``(]:Y56\1?#[46`0M`YYR"8IA_0_K7J&A
ML;K3X]0GTZ.RNKE0TBJ!D^F32CK*YEBE&E0Y;*47\+OJB+Q1JW]C:%/<*<3,
M/+B_WCT_+K7-:)IGB_2M/$=E%9*DI\PF0_.2?6N@UGP_+K.KV,\UPGV*T;>8
M"N2[?7TZ5NUW*HH0LM;[G@VN[G!:WI?B_5M/:&]CLFCC/F`QG#`CTJGK&J-J
M_@W3+YU+M9W2K<CW`QS]?ZUZ37-V?A);:_U(/*DFFWXRUL5(*MZ@_G6D*R^T
MK6_IB<7T-^VGCN;:*>$@QR*&4CTKE/B/=0)I-M:L09I+A75?89R?UHA\+Z_I
M!:'1M;5;4GY8YTW;/I27G@66\LBUQJ)N-1>16>YE7("C/RJ.PI4U3A-2YM`=
MVK6#5+C4-6\20>'[:\:SMTMQ+,\?#N/05<_X0JSB7?'J6HQ2+SYGVDG'OSQ4
MFM>%WOKJ#4;"\:SU"!0HD`RK@=B*A&B>(=0'DZMK*"U/WX[6/8T@]"WI1S+E
M7+*W<+:ZHY:TQ_P@6M`.7'VH8<_Q<CFNZ\,7,%UX<LG@P%6((5'\)'!%<UJF
M@-X?\$ZI`9ED668.FT$;1D8%6;'PW>Q6%K?:%J)LI)H5::%QNC=L=<=C6E3E
MG%Z]?T%&Z9I^-KF&W\*W@E(S*`B#U;(__77/Z]$\'@/1XY00PDC)S^)K3M_"
M-Y?7\=YXAU'[;Y1RD"#"`UL:_HD.O:6UE(YB((:-P/NL.G'I6<9QARQO?6[&
MTW=FFOW1]*\]T_\`U?C#ZM_[-70:/I'B&SNH?M^LK<6L((\M4Y?TR:9;>%9H
M%UL&ZC;^TR2F$/R9SU]>M*#C"ZOV_,;NRUX,_P"13L/^N?\`4UF^+?\`D9?#
MO_7S_45O:'ISZ3H]O8/()&A7!91@&JNLZ%)JFJZ9>).L:V,N]E*Y+<CI^5*,
MXJJY=-0:?+8VJX;0O];XM_WY/Y-7<US^G^&Y;)]99KE'_M)F*X4C9G/7UZU-
M.246GY?F.2U0G@3_`)%"R_X'_P"A&L_QW_Q_:'_U\G_V6M[P]I3Z+HL&GR2K
M*T6<NHP#DD_UJOXAT"76KBPDCN$B%I+YA#*3NZ<?I51G'VSETU$T^6QMUPE@
M"?$?BT`<F`X_(UW=8>F:!)8Z_J>I23I)'?8Q&%Y7'KZU-.2BI7_K4<E>Q6\`
M2(_A2!58$H[*P]#G/]:J_$>9$T."(GYY+A=H^G6D/A#4],OI9_#^J"VAF.6A
MD7(%-OO!%YJ5J9+[5?/OBPQ(Z_)&HZA0/7UK9.G[7VG-H3KRVL1ZN`?&GAW(
MS^Z']:[:L&]\/2W6NZ9J(N$5;%`K(5.6^AK>K&I)-1MV*BK7/-KB&2?4/&$<
M2%F,:G`]`V3^@J_X>TC4]1T.VN+/Q+/#%MVB)8QB,CM6]IGA^2QU_4]2DG22
M.^P!'MY7Z^M4)/"=_IMY)<>'=2^R)*=SV\J[DS[5NZL6N5/M^1'*]R*]\':E
M?0>1>^)9I8F8':\8QGMWKK88_*@CCSG8H7/K@5S,'A?4KV]BNM>U4W"PL'C@
MA&Q`P[FNIK"K*]E>Y<4%-:-'*LR*2IRI(S@^U.HK$H\\U[P_XJUG6!!<2));
M9S'(IVQH/<=<UUV@:!:Z!9>1!\\C<RRD<N?\/:M6BMIUI2BH[(E12=Q*\\\7
M?#Z22=M2T)0')W/;`[>?5#V^E>B45SRBI*S.K#XBIAY\T&<[X4M-<&E>7XB>
M.7./+C=0SJ!_>/0FNBHHII61G4J.I)RM:_8HC6=/.H_V<+D?:O\`GEM.?Y8H
MGUG3K:^6RFNDCN'QA#GOTYZ<TX6`&KG4=_)@$.S'^T3G/XU0O_#4=]JPU%KE
MU<-$1'C*'82<$9YSG\,4M2XJBWJW:WX_<:=W?6MA&DEU,L*NXC4MW8\`4ZZN
M[>RB$MS*L2%@FYNF2<`?G69KWAV/Q!Y27%W-%%$"52+`^<]&)]O2I[[1UU+2
MX;"[E\U49#(Q7_6;3SD=LT:B4:5HW?J6UO+=H9)A,OEQ%E=R<!2O!S],4VSU
M"TU"V-Q:S"2($@M@CI]:J:?HB:?H\FFK.TJ.9"'D`8@,2<'/7&<4:/HW]DV,
MEK]I,H=B1\NT)D8P!DX'XT]0<:=G9]=/0L6&JV.IJS64XF"=2%(_F*2#6-/N
M;U[*&[C>=,Y0>W7!Z''?%,T?1K?1K);>#<QP`[DGYB.^">/PJI8^'!9W<#F\
M:2WM&D:WAV`;"_7+=6ZFEJ-JC>5F[="75KG1KUFT;4)UW2[<Q$D=>G/3G%6#
M=:?I20V;SI"%B)C5S_`HY/X"J5YX:CO-7.HFY=7WQ-Y?5#LSP1GGK^&*DU?P
M[::U=PS7GS+#&RA,=R0<Y_#I[T^:5K#4:%U=O;7U+PU"T-BEZ)U^SN%*R=CD
MX'\Z=/>VUK+#%/,D;SDB-6/WB!DX_"J1T53H,6E>>=L80>9MY.U@>GX4FM:#
M!K9A^T2,HA#[=O4%A@,#V(Q2U)4:7-J]-?\`@%UK^T2Q^W-.BVVP/YI.!@]Z
M6SO;>_MUN+63S(F)`;!'3V-49="270(=*:=OW"H$EP,[DP0<?4=*ETC3&TNW
MEC>X:=Y93*S$8`)QP!DX''K3UN#5/E;3UO\`@7R0JECT`R:IV&KV&J&065P)
MO*.'PI&/S%7:J:?8"P%SB0OY\[S=,8W=J-2%R\KOOT$OM6L--:-;RY6)I/N@
M@DGWX[>].O=1M-/1&NIA&)&VIP26/7@"JU]I4MQJ$=]:WGV:98C"V8@X9"<]
M#T/O3-=T/^VH[=?/$1@DWC<FX-QCG!'KZTM32,:5XW?K_5O\S0>[@CACE>0*
MDK*J$@\EN@I;BYAM8Q)/($0L%!/J3@#\S52_TV2\T^&W6X$4L+QR+)Y>1E3G
M[N>GXTE_IL^H:6MK)=*LZNC^<(N"RL&^[GIQZT]25&&EWU_`T:IZAJMCI2(]
M]<"%9#M4D$Y/IQ5B!94@19Y%EE`^9U7:"?IDXJMJFG+J=O'"TAC\N:.7(&<[
M6!Q^.*'>VA,%'FM+8F:\MU2%FE`%P0L6?XB1D4P:E9FP:^$Z_9E!)DYP,'!J
M+5=)AU9((YV(CAF$A4?Q8!XR.G6JT?A](_#3Z(LYV,C()-O(R2>GXTM2TJ5E
M=ZW_``+\%_;7-JUS%)F)<Y8J1C'7J*;8:I8ZFC/97"S!<;L9!&>G!J"QTDVF
MD2:>TRL'5E#(A7&1Z$G^=1Z+H,>BF;RYWF$H09DY9=JXQDGIWQVHU&XTK2L]
M>A?BO+:>YFMHID>:`@2H#RF1D9J$ZOIXU'^SC=(+K_GF<YZ9QZ=*H:;X;&FZ
MH^HK?32S3;_/5P-K[CD8';'XU,GA^U_MJ;592TLKNKQJ20L9"[<XS@GW-&HW
M&BF]6U;\2W/JEC;3-#-<*DB[<J<Y^8X7'KDU;JA=Z3#=ZK9:@^-]INP"N=V1
MZ^W6K]-7,I<MER_,****9`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g114961mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g114961mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!"`2T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBJ.H:Q
MI^F211WMTD#S'";N]-)O1`7<C.,\TM>;>)=-U_3K[^W8-1>[B'*S1G_5KZ8'
M&VNE\)^*H]>@,$^V.]B&74<!Q_>'^%;2HM0YXNZ(4M;,Z2D)P,FFR2)#&TDC
M!$0$LQ.`!7E7B+Q9J7BG4/[)T191;,VU5CX:;W)[+7-*2B=N&PL\1*RT2W?8
M]7SFEKD-%8^#-)6/Q%KD9WX\N%N?+]@>I'Z5UD<B2QK)&P9'`*L.A%-.YE5I
M<CT=UT?1CZ***9D%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`UF"*68X51DGT%<1J6G:+XVN)+C3]49
M;Y5VB.3[I`_V3SCW%=K/"MQ;R0.2%D4J<'!P1BO/M1\!ZEI^I17.@,75/F4O
M(%:-AVSW%=-#E3?O69$[]BGH&LWGAG56T?55)M&;RY(WY"9_B'M4>O64GA'Q
M/#>V/$#GS8O3'\2_3^AKH?%_AF_UR&RNK>W3[8J;9UW@=O7OSFG:YX=U35?"
M>G6[1*^HVQ`<%P!C&#ST["NE5874N^C,^5[%#XB^(P=$M+.T?`OT$KD'GR_3
M\3_*J^FB#P+X0&JR1*^JZ@`(E;^$'D#Z`<FJ<O@CQ'?7UC]IM8Q!;JD3'SE.
M%#9)Q^-:_CGPSKFOZM;_`&*"-K2&(*K&0#!)YX_`5Y%1-3DU\CZ.C*C[*G1<
MDD]9:_A_78YS1/#5]XLEEUC5KQH;0$E[B0\MCJ%SP`*]!\+ZEHC0'1](O'N1
M9IU?)R,]CW_"LCQ;X?UFZTFQT;1($^Q0H/-'F!-Q'0<]>YJ]X2\%P^'@EW)-
M(]Z\>V7#?(,\X`_K2BFG9(C$UJ=:BY2E_ABNGJ=36#XMUJ72-+46A_TRY<1P
M#&3GN<=__KUO5QUL?^$C\=27/WK/21LCYX:3U_SZ"NNE%-\SV1XDGT1I>$-:
MGU;39([X_P"FVLACF!7!]CC]/PK?KC+[_BF_',-\/EL]4'ER^@?U_/'ZUO\`
MB'6H]!TF2\90[_=C0G[S'I53A>2<>HD[+7H:E<UX[O+FRT*.6TN)()#<HI:-
ML''/%4;/PYK6LPK?:MK5Q`\HW)#!P$!Z?_JK)\6#6--T^+3-1G^W6\DRO!=$
M88$9RK?G6E*E'VB5[BE)VV/1HB3$A)R2HI]8^K6&J7]K;1Z=J7V$`?O6"Y)&
M.,5D3^%-:MHFGL?$=T]PHSMD^ZY]*QC"+WE8IM]CKZ*XB7Q)>7_@.YO%D:WO
MK=Q%(\?'((Y'X4[3;;7/%-A#//J,MC8A`JK'_K)L=6)]S5>Q:5Y.W07-V.UK
M%\3ZW-H=A#<01)(TDRQD/G&#6!?1ZWX,:.]2_DU'3=X66.7[R`_YZU#XY@GN
MK6VU2+4I&L[AXQ';8^521][KUJZ=)<ZN[IB<M&=\#D`^M9NE_P!L_;+[^TC#
M]G\S_1?+Z[??].M4-+T#5[.^BN+GQ'<7<2_>A=,!N/K618ZIJ#IXI+WDS?9B
M?(RW^K^]T]*A4[I\K3V_,=^YW-%<+H=IK?B?289;O59[:T0%1Y9_>3$=6)],
M_P`J@N+W7O!^HK8"X;4HKM,6QEZA\X'_`.KO3]AJXIZAS];'H-%<A)X1UBXA
M^TS>(KG[?]X;>(U/I3_#^MWU[H.IPWK8O=/5T:0<$G:<'ZC%2Z2M>+N/F[HZ
MRBN"\/PZ[XHTB+[3JD]M:Q$J73F2<YSDGT'`_"H[RZUOP3?)%]J;4;2Z4B$2
MGD/V_F/K5>PU<4]1<^E['H-%<@?">L7L/VF[\07"7K#<%CXC0^F*;H.N:A-I
MFKV%_(3?:=&^)1U(P<'ZY%3[)-7B[CYNYV-%8/@N[N+WPS;SW4SS2L6R[G)/
M-0>.KVZL-#26TN)()#.JEHS@X]*E4W[3D#FTN=+17$>)=6U6SUS2(K"9V::$
M?N=V%D8G`W5:E\(ZM<1FXF\1W/VWJ-O$:^P%7[)))RE:X<W9'6T5R7AGQ'<?
M8]0M]9<&?3,[W[LHS^N1^-5].M=7\8(=0N]1FL;!V/D06YP2!W)I>Q:;YG9(
M.;L=K17%33:GX,U"V^T7TE_I5P_EGS?OQ'ZUV@((!!R#T-3.'+9[IC3N1W,K
M0VLLJ)O:-"P7^\0.E>73ZGK?C35XH[426Z+\N(G8+&.Y8CK7JM<5XLUV_P!`
ME&GZ9816T<XRDZ+RQ[X`[UMAGJTEJ1/8SO'.IFW-EHUE<RE[9!YC)(02V,`$
M^O?\:F\57%QI/A'2M-:YD%TV&D<.0V`.<GKU/Z5#X>\-FT8^(/$3&&.(^8J2
MGYG;U;_"L]FN?'/BP85D@!Q_USB!_F?ZUTQ4;I=(ZM^9#O\`>95_+J&BWVEW
M3W=UMEBCN"&F;!.[D=>G`K=^)#7<&H6.JV=W.+>YB`!CD8)D<CH<<@_I6_X_
M\.?VEH4<UG%F:P&511]Z/'(_3-<_X7U*R\2Z"WA75I-DJC_1)3UXZ`>X].XK
MQJCYIR\]3Z?#S7L:=5*_)I+T[ESQ/'=^)O#EEKNC3SEXH]MQ##(P/OP.I!_2
MK?@+Q9?ZQ)_9=W`'-K%EKC)#$#``(]:Y56\1?#[46`0M`YYR"8IA_0_K7J&A
ML;K3X]0GTZ.RNKE0TBJ!D^F32CK*YEBE&E0Y;*47\+OJB+Q1JW]C:%/<*<3,
M/+B_WCT_+K7-:)IGB_2M/$=E%9*DI\PF0_.2?6N@UGP_+K.KV,\UPGV*T;>8
M"N2[?7TZ5NUW*HH0LM;[G@VN[G!:WI?B_5M/:&]CLFCC/F`QG#`CTJGK&J-J
M_@W3+YU+M9W2K<CW`QS]?ZUZ37-V?A);:_U(/*DFFWXRUL5(*MZ@_G6D*R^T
MK6_IB<7T-^VGCN;:*>$@QR*&4CTKE/B/=0)I-M:L09I+A75?89R?UHA\+Z_I
M!:'1M;5;4GY8YTW;/I27G@66\LBUQJ)N-1>16>YE7("C/RJ.PI4U3A-2YM`=
MVK6#5+C4-6\20>'[:\:SMTMQ+,\?#N/05<_X0JSB7?'J6HQ2+SYGVDG'OSQ4
MFM>%WOKJ#4;"\:SU"!0HD`RK@=B*A&B>(=0'DZMK*"U/WX[6/8T@]"WI1S+E
M7+*W<+:ZHY:TQ_P@6M`.7'VH8<_Q<CFNZ\,7,%UX<LG@P%6((5'\)'!%<UJF
M@-X?\$ZI`9ED668.FT$;1D8%6;'PW>Q6%K?:%J)LI)H5::%QNC=L=<=C6E3E
MG%Z]?T%&Z9I^-KF&W\*W@E(S*`B#U;(__77/Z]$\'@/1XY00PDC)S^)K3M_"
M-Y?7\=YXAU'[;Y1RD"#"`UL:_HD.O:6UE(YB((:-P/NL.G'I6<9QARQO?6[&
MTW=FFOW1]*\]T_\`U?C#ZM_[-70:/I'B&SNH?M^LK<6L((\M4Y?TR:9;>%9H
M%UL&ZC;^TR2F$/R9SU]>M*#C"ZOV_,;NRUX,_P"13L/^N?\`4UF^+?\`D9?#
MO_7S_45O:'ISZ3H]O8/()&A7!91@&JNLZ%)JFJZ9>).L:V,N]E*Y+<CI^5*,
MXJJY=-0:?+8VJX;0O];XM_WY/Y-7<US^G^&Y;)]99KE'_M)F*X4C9G/7UZU-
M.246GY?F.2U0G@3_`)%"R_X'_P"A&L_QW_Q_:'_U\G_V6M[P]I3Z+HL&GR2K
M*T6<NHP#DD_UJOXAT"76KBPDCN$B%I+YA#*3NZ<?I51G'VSETU$T^6QMUPE@
M"?$?BT`<F`X_(UW=8>F:!)8Z_J>I23I)'?8Q&%Y7'KZU-.2BI7_K4<E>Q6\`
M2(_A2!58$H[*P]#G/]:J_$>9$T."(GYY+A=H^G6D/A#4],OI9_#^J"VAF.6A
MD7(%-OO!%YJ5J9+[5?/OBPQ(Z_)&HZA0/7UK9.G[7VG-H3KRVL1ZN`?&GAW(
MS^Z']:[:L&]\/2W6NZ9J(N$5;%`K(5.6^AK>K&I)-1MV*BK7/-KB&2?4/&$<
M2%F,:G`]`V3^@J_X>TC4]1T.VN+/Q+/#%MVB)8QB,CM6]IGA^2QU_4]2DG22
M.^P!'MY7Z^M4)/"=_IMY)<>'=2^R)*=SV\J[DS[5NZL6N5/M^1'*]R*]\':E
M?0>1>^)9I8F8':\8QGMWKK88_*@CCSG8H7/K@5S,'A?4KV]BNM>U4W"PL'C@
MA&Q`P[FNIK"K*]E>Y<4%-:-'*LR*2IRI(S@^U.HK$H\\U[P_XJUG6!!<2));
M9S'(IVQH/<=<UUV@:!:Z!9>1!\\C<RRD<N?\/:M6BMIUI2BH[(E12=Q*\\\7
M?#Z22=M2T)0')W/;`[>?5#V^E>B45SRBI*S.K#XBIAY\T&<[X4M-<&E>7XB>
M.7./+C=0SJ!_>/0FNBHHII61G4J.I)RM:_8HC6=/.H_V<+D?:O\`GEM.?Y8H
MGUG3K:^6RFNDCN'QA#GOTYZ<TX6`&KG4=_)@$.S'^T3G/XU0O_#4=]JPU%KE
MU<-$1'C*'82<$9YSG\,4M2XJBWJW:WX_<:=W?6MA&DEU,L*NXC4MW8\`4ZZN
M[>RB$MS*L2%@FYNF2<`?G69KWAV/Q!Y27%W-%%$"52+`^<]&)]O2I[[1UU+2
MX;"[E\U49#(Q7_6;3SD=LT:B4:5HW?J6UO+=H9)A,OEQ%E=R<!2O!S],4VSU
M"TU"V-Q:S"2($@M@CI]:J:?HB:?H\FFK.TJ.9"'D`8@,2<'/7&<4:/HW]DV,
MEK]I,H=B1\NT)D8P!DX'XT]0<:=G9]=/0L6&JV.IJS64XF"=2%(_F*2#6-/N
M;U[*&[C>=,Y0>W7!Z''?%,T?1K?1K);>#<QP`[DGYB.^">/PJI8^'!9W<#F\
M:2WM&D:WAV`;"_7+=6ZFEJ-JC>5F[="75KG1KUFT;4)UW2[<Q$D=>G/3G%6#
M=:?I20V;SI"%B)C5S_`HY/X"J5YX:CO-7.HFY=7WQ-Y?5#LSP1GGK^&*DU?P
M[::U=PS7GS+#&RA,=R0<Y_#I[T^:5K#4:%U=O;7U+PU"T-BEZ)U^SN%*R=CD
MX'\Z=/>VUK+#%/,D;SDB-6/WB!DX_"J1T53H,6E>>=L80>9MY.U@>GX4FM:#
M!K9A^T2,HA#[=O4%A@,#V(Q2U)4:7-J]-?\`@%UK^T2Q^W-.BVVP/YI.!@]Z
M6SO;>_MUN+63S(F)`;!'3V-49="270(=*:=OW"H$EP,[DP0<?4=*ETC3&TNW
MEC>X:=Y93*S$8`)QP!DX''K3UN#5/E;3UO\`@7R0JECT`R:IV&KV&J&065P)
MO*.'PI&/S%7:J:?8"P%SB0OY\[S=,8W=J-2%R\KOOT$OM6L--:-;RY6)I/N@
M@DGWX[>].O=1M-/1&NIA&)&VIP26/7@"JU]I4MQJ$=]:WGV:98C"V8@X9"<]
M#T/O3-=T/^VH[=?/$1@DWC<FX-QCG!'KZTM32,:5XW?K_5O\S0>[@CACE>0*
MDK*J$@\EN@I;BYAM8Q)/($0L%!/J3@#\S52_TV2\T^&W6X$4L+QR+)Y>1E3G
M[N>GXTE_IL^H:6MK)=*LZNC^<(N"RL&^[GIQZT]25&&EWU_`T:IZAJMCI2(]
M]<"%9#M4D$Y/IQ5B!94@19Y%EE`^9U7:"?IDXJMJFG+J=O'"TAC\N:.7(&<[
M6!Q^.*'>VA,%'FM+8F:\MU2%FE`%P0L6?XB1D4P:E9FP:^$Z_9E!)DYP,'!J
M+5=)AU9((YV(CAF$A4?Q8!XR.G6JT?A](_#3Z(LYV,C()-O(R2>GXTM2TJ5E
M=ZW_``+\%_;7-JUS%)F)<Y8J1C'7J*;8:I8ZFC/97"S!<;L9!&>G!J"QTDVF
MD2:>TRL'5E#(A7&1Z$G^=1Z+H,>BF;RYWF$H09DY9=JXQDGIWQVHU&XTK2L]
M>A?BO+:>YFMHID>:`@2H#RF1D9J$ZOIXU'^SC=(+K_GF<YZ9QZ=*H:;X;&FZ
MH^HK?32S3;_/5P-K[CD8';'XU,GA^U_MJ;592TLKNKQJ20L9"[<XS@GW-&HW
M&BF]6U;\2W/JEC;3-#-<*DB[<J<Y^8X7'KDU;JA=Z3#=ZK9:@^-]INP"N=V1
MZ^W6K]-7,I<MER_,****9`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
